Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2026Clinical Physiology and Functional ImagingOpen Access

Twelve-week mavacamten treatment significantly reduced resting and provoked LVOT gradients (p<0.001) and improved myocardial work efficiency (GWE) in patients with oHCM.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

To evaluate the effect of 12-week mavacamten on left ventricular function in obstructive hypertrophic cardiomyopathy using myocardial work analysis, and explore its role in myocardial energy metabolism.

Does mavacamten improve left ventricular function and myocardial work parameters in patients with obstructive hypertrophic cardiomyopathy?

Population

35 oHCM patients and 35 matched healthy controls

Comparison

12-week mavacamten treatment in oHCM vs baseline and healthy controls

Follow-up

12 weeks

Key result

Twelve-week mavacamten treatment significantly reduced resting and provoked LVOT gradients (p<0.001) and improved myocardial work efficiency (GWE) in patients with oHCM.

Authors

LWLi WanXCXixi ChenZHZiwei Huang

Discussion

Loading...

Member takes

Overview

Myocardial work parameters may track Mavacamten response in oHCM; leaves open whether energy metabolism changes affect outcomes in prospective trials.

Study Design

Type

Observational (n=70)

Structured PICO

Does mavacamten improve left ventricular function and myocardial work parameters in patients with obstructive hypertrophic cardiomyopathy?

P
Population
35 patients with obstructive hypertrophic cardiomyopathy and 35 matched healthy controls, evaluated over 12 weeks of mavacamten treatment.
I
Intervention
Mavacamten for 12 weeks
C
Comparator
Baseline values (pre-treatment) and matched healthy controls
O
Outcome
Left ventricular function and myocardial energy metabolism assessed by myocardial work parameters (GWI, GCW, GWW, GWE), LVOT gradient, LVEF, GLS, mitral regurgitation severity, and SAMsurrogate

Main Result

p-value: p=<0.001

Mavacamten reduces LVOT obstruction and improves myocardial work efficiency in oHCM patients over 12 weeks while preserving systolic function.

Cite This Study

Wan et al. (2026) conducted an observational in obstructive hypertrophic cardiomyopathy (n=70). Mavacamten vs. Baseline and healthy controls was evaluated on Left ventricular function and myocardial work parameters (GWI, GCW, GWW, GWE) (p=<0.001). Twelve-week mavacamten treatment significantly reduced resting and provoked LVOT gradients (p<0.001) and improved myocardial work efficiency (GWE) in patients with oHCM.

synapsesocial.com/papers/6a6e846935aa2c282ce04cf8https://doi.org/10.1111/cpf.70084
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mavacamten optimizes myocardial work in patients with obstructive hypertrophic cardiomyopathy: a non-invasive pressure–strain analysis2026 · 1 citations
  2. 2Mavacamten effectively reduces > 100 mmHg left ventricular outflow tract gradients as early as one week of treatment in obstructive hypertrophic cardiomyopathy2025 · 3 citations
  3. 3Echocardiographic changes with mavacamten in patients with obstructive hypertrophic cardiomyopathy: early experience from a referral center2026
  4. 4The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients, a systematic review and meta-analysis2025 · 4 citations
  5. 5Effect of Mavacamten on left ventricular diastolic function and left atrial function in obstructive hypertrophic cardiomyopathy2025